leisure time -WSS

leisure time

author：comprehensive 2025-09-30 17:43:58 - browse：5

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： ‘The Bear’ and hospitality in hospitals

WSS

First transplant of an entire human eye performed

In venture capital firm's success, lessons for turning crisis into profit

Carbon Health diabetes program, a test of data

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Weight loss drugs should be covered by insurers, AMA says

Experimental asthma app from Apple and Anthem shows promise

knowledge

leisure time

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC launches VaccineFinder tool to locate Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Experimental asthma app from Apple and Anthem shows promise

The cancer drug shortage isn’t new — and neither are the solutions

Study suggests Covid rebound is far more common with Paxlovid than without

Novavax promises a turnaround & Lilly roils the obesity market

What is STAT's opinion section for?

In Memoriam: Notable people who died in 2023

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

Experimental asthma app from Apple and Anthem shows promise

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Discs beat pads, tampons for heavy menstrual flow, new study shows

Cancer diagnosis changes perspective doctor, former hospital CEO

Ohioans vote in high

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

leisure time

focus

hotspot

entertainment